A share price of Mineralys Therapeutics Inc [MLYS] is currently trading at $10.52, down -0.19%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The MLYS shares have gain 15.10% over the last week, with a monthly amount glided 2.53%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Mineralys Therapeutics Inc [NASDAQ: MLYS] stock has seen the most recent analyst activity on July 10, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $30. Previously, Goldman started tracking the stock with Buy rating on April 02, 2024, and set its price target to $30. On March 07, 2023, Wells Fargo initiated with a Overweight rating and assigned a price target of $27 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $45 on March 07, 2023. Guggenheim initiated its recommendation with a Buy and recommended $32 as its price target on March 07, 2023. In a note dated March 07, 2023, Credit Suisse initiated an Outperform rating and provided a target price of $40 on this stock.
Mineralys Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $8.24 and $15.25. Currently, Wall Street analysts expect the stock to reach $30 within the next 12 months. Mineralys Therapeutics Inc [NASDAQ: MLYS] shares were valued at $10.52 at the most recent close of the market. An investor can expect a potential return of 185.17% based on the average MLYS price forecast.
Analyzing the MLYS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -0.68 and Total Capital is -1.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.22 points at the first support level, and at 9.91 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.80, and for the 2nd resistance point, it is at 11.07.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Mineralys Therapeutics Inc [NASDAQ:MLYS] is 14.02. As well, the Quick Ratio is 14.02, while the Cash Ratio is 7.79.
Transactions by insiders
Recent insider trading involved Levy Adam Scott, CFO and Secretary, that happened on Jan 13 ’25 when 10757.0 shares were sold. Chief Executive Officer, Congleton Jon completed a deal on Jan 13 ’25 to sell 18333.0 shares. Meanwhile, Officer Congleton Jon bought 18333.0 shares on Jan 13 ’25.
